MVMD has the best pharmacokinetic data for Ivermectin in the world and the implications for both human and animal health are tremendous.

Five times more tremendous in fact.

#MVMD
Moves Faster

MVMD is here to change the world. To push the boundaries of science and exploration. To go beyond possible… and reach for the stars into the universe of all things impossible. 

Our patented technologies are embedded across critical projects that are focused on doing more with less, making world-class drugs and vaccines more accessible, and driving significant inefficiencies and costs out of the legacy manufacturing and distribution systems.   

Review our product pipeline below for a detailed overview of our key initiatives and related status.

Swipe to View Pipeline.

Program

Tech

Market

Value Proposition

Dose Sparing Adjuvant

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Dose Sparing Adjuvant

Patent-Pending Porous Aluminum Nanostructure Adjuvant has high surface area for vaccine-antigen binding to provide dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.

Adjuvant

Vaccine

Use less vaccine per dose, cost reduction, increase vaccine output, facilitate mucosal and herd immunity, long-term stability in aqueous media, promote greater stability in harsh environments, inform significant dose sparing applications across hundreds of vaccines, key to global disease eradication 

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation Lab Work
Completed
Electron Micrograph Quantification
Completed
Porous Aluminum Nano-Structured Adjuvant Patent filing / Acceleration Review Request
Completed
Tulane Trials – Dose Sparing and Mucosal Immunity 

The study will compare existing Alhydrogel adjuvant to the Company’s recently invented stable nano-particulate adjuvant by both intramuscular injection and intradermal injection immunization, evaluating the antibody responses following vaccination with fractional doses of IPV comparing delivery types with IPV alone or adjuvanted.

Tulane Trials – Dose Sparing and Mucosal Immunity 
In Progress
Partnering Licenses
In Progress
Human Trials
Pending
Expanded Spectrum Vaccine Dose Sparing Evaluations
Pending

Cold Chain

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Dose Sparing Adjuvant

Patent-Pending Porous Aluminum Nanostructure Adjuvant has high surface area for vaccine-antigen binding to provide dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.

Adjuvant

Vaccine

Enable distribution outside of cold chain, use less vaccine per dose, cost reduction, increase vaccine output, key to global disease eradication

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation Lab Work
Completed
FDA confirmation of stabilization and preservation of Polio D Antigen via Quicksome™
Completed
Preliminary cold chain testing: 25°C
Completed
Optimization work, vial embed, rapid dry
Completed
FDA cold chain testing on novel desiccated vial format: 30º C - 45º C
In Progress
Manufacturing Application / Elisa validation
Pending
Quicksome™ sublingual vaccine pre-clinical / clinical trials
Pending
Sublingual Partnering Licensing
Pending

Macrocyclic Lactone Solubilization

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Drug, Human Therapeutic, Animal Parasitic

Significant improvement over current oral form ivermectin drug –waterless oral dissolve, dramatically quicker onset, zero decline over extended periods in the body, less variability, requires a fraction of the Ivermectin API, uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), leading candidate for human injection and sublingual applications, broader husbandry and companion animal applications based on low viscosity. Implications for COVID-19 viral clearance, prophylactic, and broader applications for the elimination of malaria and dengue. 

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation lab work on solubilization of Ivermectin
Completed
Patent filing for macrocyclic lactone drugs. Accelerated application examination requested.
Completed
Pre-clinical trials for solubilized rapid dissolve and intramuscular delivery

MVMD has the best pharmacokinetic data for Ivermectin in the world with broad implications for both human and animal health.  Pre-clinical key findings:

• MVMD’s solubility technology delivered 800% increase in bio availability through intramuscular (IM) injection and 500% increase in bio availability through sublingual compared to oral tablets.

• MVMD’s IM injection reaches TMAX (the time to reach the maximum concentration of Ivermectin in the body) at 15 minutes compared to current commercial oral and subcutaneous forms which take between 6 and 36 hours and is well documented.  The Company’s sublingual strips had a TMAX of1 hour, a 600% increase over oral tablets.

• Both MVMD applications showed zero decline in CMAX (peak serum concentration that a drug achieves) over an extended timeframe of 12 hours, with gradual decline over 96 hours (vs 36 hours for oral tablet) almost 3x extended clearance - a very significant indication over oral and subcutaneous forms.

• Both MVMD applications show minimal pharmacokinetic variability, with IM injection at zero percent variability and sublingual strips at 5% variability compared to40% variability for oral tablets. Variability contributes to the potential for adverse effects or not achieving the required therapeutic index.

Pre-clinical trials for solubilized rapid dissolve and intramuscular delivery
Completed
API sourcing / supply contracting
Completed
BSL-4 COVID-19 Clearance trial

Bio Safety Level 4 (“BSL-4”) lab study of COVID-19 viral clearance in transgenic mice designed to prove the superiority of the Company’s solubilized Ivermectin technology versus commercially available oral form in speed and efficacy of viral clearance. Demonstration of how solubility technology  applied to the Ivermectin drug can be applied as a broad therapeutic to immediately treat COVID-19, as well as its role in stopping the deadly spread of future pandemics, including a world’s first as an injectable Ivermectin format for emergency front line usage as well as a rapid dissolve tablet that  is administered for prevention like vitamin C around the world.

There are less than thirty BSL-4 facilities in the world capable of performing this  study and it is not unusual for projects to take up to three years to  schedule. The Company was able to demonstrate the significance of its patented solubilized Ivermectin technology through its presentation of the superior pharmacokinetic data documented from two previously completed pre-clinical trials.

This study will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was  led by the Company’s key scientific advisor,
Dr. John Clements.   

BSL-4 COVID-19 clearance trial
Completed
Sourcing husbandry animal pre-clinical applications
Completed
Conducting husbandry clinical trials: Cattle, Swine, Poultry
In progress
Conducting husbandry clinical trials: Cattle, Goat, Poultry
In progress
GLP production of solubilized ivermectin for rapid dissolve and intramuscular formats
In progress
505(b)(2) pathway with the U.S. Food and Drug Administration (FDA)
In progress
Human clearance trial
Pending
Human partnering licenses / ivermectin production evaluation
In Progress
Targeted first revenues
In Progress
Animal partnering licenses / MVMD production evaluation
Pending

Cancer

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Oncology

Ivectosol™ being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Initial Ivermectin Oncology Research
Completed
Patent filing for cancer adjuvant, Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies for its solubilized ivermectin (Ivectosol™).
Completed
Preclinical Study One: Triple-negative breast cancer

Study will test the effectiveness of Ivectosol™ combined with checkpoint inhibitor that would be equivalent to either OPDIVO or Keytruda for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor.

Triple-negative breast cancer
In Progress
Estimated initial readouts/analysis
In Progress
Complete readout with flow cytometry and statistical evaluation
In Progress
Preclinical Study Two: Metastatic melanoma

Study will test the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + check pointinhibitor and intratumoral IVM + checkpoint inhibitor

Metastatic melanoma
In Progress
Estimated initial readouts/analysis
In Progress
Complete readout with flow cytometry and statistical evaluation
In Progress
Preclinical Study Three: Lewis lung carcinoma as a proxy for non-small cell lung carcinoma

Study will test the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor, intratumoral IVM + checkpoint inhibitor, navalbine + intratumoral IVM

Lewis lung carcinoma as a proxy for non-small cell lung carcinoma
In Progress
Estimated initial readouts/analysis
In Progress
Complete readout with flow cytometry and statistical evaluation
In Progress

Expanded Ivermectin Applications

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Human Parasitic, Therapeutic, Animal Parasitic

Enhanced treatment options and effectiveness across broad ectoparasitic applications.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Invitro testing for targeted ectoparasites control - lice, ticks, bedbugs
Pending
Pre-clinical to test liquid shampoos, drenches for both animal and human health applications
Pending
Partner licensing
Pending

Selamectin

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Human Parasitic, Therapeutic, Animal Parasitic

No current human forms – solubilized pursuit would open up applications similar to MVMD’s work with ivermectin – waterless oral dissolve, inhalable, or injectable, dramatically quicker onset, zero decline over extended periods in the body, less variability, requires a fraction of the API, uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), leading candidate for human injection and sublingual applications, broader husbandry and companion animal applications based on low viscosity.  Pursuing implications for Tuberculosis treatment.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Solubilization and formulation work on Selamectin
Completed
Pre-clinical trials for solubilized rapid dissolve and intramuscular delivery
Pending
Phase I trial
Pending
Human partnering licenses / production evaluation
Pending
Animal solubilization pre-clinical
Pending
Animal partnering licenses / MVMD production evaluation
Pending

Sublingual Pharmaceutical

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Applications across human pharmaceutical and vaccine space

Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing, needleless administration, pain elimination, reduced risk of infection and common site injection reactions, reduced complexities for medically supervised administration.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation work on rapid dissolve oral application with IPV for polio
Completed
FDA confirmation of stabilization and preservation of Polio D Antigen via Quicksome™
Completed
Preliminary cold chain testing – 25°C
Completed
Application of Quicksome™ and cold chainwork across BCS Class II drugs, small peptides and proteins
Pending
Partner licensing and molecule identification
Pending

Sublingual Nutraceutical

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Applications across human nutraceutical

Stable delivery, waterless oral dissolve, quicker  onset, precise dosing, reduced variability, dose sparing, needleless administration, easy to use formats. 

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation work on rapid dissolve loads across oral powder, chews, wafers and thin strips
Completed
Applications samples developed across Weight loss, Energy, Pre-workout, Recovery, Sleep, Focus, Libido, Smokeless Nicotine and a variety of natural mushroom molecules.
Completed
Quicksome™ partner licensing contracting
In Progress
Targeted First Revenues
In Progress

Insulin

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Human insulin drug

Stable sublingual delivery, waterless oral dissolve, rapid onset, precise dosing, reduced variability, needleless administration, easy to use format.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Initial stability and formulation work on rapid dissolve oral application of Humilin R & Humalog
Completed
Pre-clinical trial on efficacy of Humiln R & Humalog molecule
Completed
Enhanced absorption and more rapid tmax
In Progress
Pre-clinical trial
Pending
Phase I trial
Pending
Partner licensing
Pending

Sublingual Cannabis

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Applications across cannabis

Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation work on rapid dissolve oral application with THC, CBD
Completed
Quicksome™ partner licensing contracting
In Progress
Targeted First Revenues
In Progress

Subscribe to Updates from MVMD

Stay plugged in on everything MVMD.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy